For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221109:nRSI8386Fa&default-theme=true
RNS Number : 8386F MGC Pharmaceuticals Limited 09 November 2022
MGC Pharmaceuticals Ltd.
Compliance Release - Application for Admission to Trading
9 November 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that it is
applying for the admission to the Financial Conduct Authority's Official List,
and to trading on the Main Market of the LSE for 50,200,000 Fully Paid
Ordinary Shares (Shares) issued by MGC Pharma, with the Company is seeking
admission to trading for these Shares from 8:00am (GMT) on 10 November 2022.
Details of the 50,200,000 Shares for which these applications have been lodged
are as follows:
· 50,000,000 Shares issued to MGC employees to settle
salary/wages in lieu of cash settlement
· 200,000 Shares issued on the exercise of securities granted
under the Company's Employee Share Scheme
--Ends--
Authorised for release by the Chairman, for further information please
contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer David Lim
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.eu (mailto:info@mgcpharma.eu) info@mgcpharma.eu (mailto:info@mgcpharma.com.au)
UK Financial and Corporate Advisor UK Broker
Hannam & Partners Turner Pope
Rupert Fane / Nilesh Patel Andy Thacker
+44 7810 056 104 +44 203 657 0050
rf@hannam.partners (mailto:rf@hannam.partners) / nilesh@hannam.partners info@turnerpope.com (mailto:info@turnerpope.com)
(mailto:nilesh@hannam.partners)
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk (mailto:mgcpharma@tavistock.co.uk)
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma
company, focused on developing and supplying accessible and ethically produced
plant inspired medicines, combining in-house research with innovative
technologies, with the goal of finding or producing treatments to for unmet
medical conditions.
The Company's founders and executives are key figures in the global
pharmaceuticals industry and the core business strategy is to develop and
supply high quality plant inspired medicines for the growing demand in the
medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical
conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise
the development of targeted plant inspired medicines, to be produced in the
Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland
and has a global distribution footprint via an extensive network of commercial
partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ALSMZMGMGLDGZZM